RightFit
RecruitingPhase not listed

Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis

Detection of Phosphorylated Alpha-synuclein Through Routine Colonoscopy to Diagnose Parkinson's Disease and Related Disorders

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
40 Years to 99 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Visits mentioned: 1 visit

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "How long does participation take? * One screening visit before the colonoscopy (about 1-2 hours) * The colonoscopy procedure (same length as normally planned) * Collecting a stool sample at home (one time) This research is sponsored by CND Life Sciences and conducted at OHSU."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study looks at whether colon tissue samples can show signs of Parkinson’s disease by finding a protein called alpha-synuclein. It is for adults ages 40 to 99 with confirmed Parkinson’s disease who have agreed to a routine colonoscopy, a test that looks inside the colon.

The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is: Can doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease? Currently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Are 40 to 99 years old.
  • Have Parkinson’s disease confirmed using a set of rules called the UKPDS Brain Bank Criteria.
  • Have agreed to a routine colonoscopy to check for colon cancer or rule out other diseases of the digestive system.

Who can't join

  • Take blood thinners. Taking only Plavix 75 mg or only aspirin up to 325 mg is allowed.
  • Have had colon cancer.
  • Have had a recent illness of the digestive system or a recent surgery.
  • Are pregnant or plan to become pregnant before the colonoscopy.
  • Have major problems with memory or thinking, as judged by the study team.
  • Cannot show that they understand the study is research and joining is their choice.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Adults 40 to 99 years of age * Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria * Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases Exclusion Criteria: * Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed) * History of colon cancer * Recent gastrointestinal illness or surgical procedures * Pregnant or planning to become pregnant before the scheduled colonoscopy * Significant cognitive impairment, as determined by study investigators * Decisionally impaired adults who cannot express understanding that this study is voluntary and for research purposes

Study sites (1)

OR